Lamotrigine Svus

Lamotrigine, the active ingredient in Lamotrigine Svus, is an anticonvulsant presented as an oral tablet for oral use. It is used to treat partial seizures, generalized tonic‑clonic seizures, and as maintenance therapy for bipolar disorder in adults. It is indicated for patients who require long‑term seizure control and mood stabilization, and it is available in the European market under a generic designation.

GNH USA supplies Lamotrigine Svus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Lamotrigine is employed in the management of seizure disorders and mood stabilization, targeting specific neurological pathways. - Partial seizures: Reduces the frequency and severity of focal onset seizures, improving patient quality of life. - Generalized tonic‑clonic seizures: Helps prevent the occurrence of bilateral convulsive seizures in patients with epilepsy. - Bipolar disorder (maintenance therapy): Stabilizes mood and decreases the risk of depressive and manic episodes during long‑term treatment.

Lamotrigine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Nausea - Rash - Blurred vision - Fatigue

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe skin reactions (e.g., maculopapular rash) - Aseptic meningitis - Hematologic abnormalities (e.g., agranulocytosis) - Hepatotoxicity - Suicidal thoughts or behavior

When prescribing lamotrigine, clinicians should consider several precautionary measures to ensure patient safety. - Initiate therapy at low dose: Reduce risk of rash by gradual titration. - Monitor skin reactions: Discontinue immediately if a severe rash develops. - Assess hepatic function: Adjust dosing in patients with liver impairment. - Evaluate renal function: Use caution in severe renal disease. - Pregnancy considerations: Category B, but discuss risks and benefits with the patient. - Store at ambient temperature: Keep below 25°C in original packaging, protect from moisture.

Lamotrigine’s pharmacokinetic profile leads to several clinically relevant drug interactions that may require dose adjustment or monitoring.

Major Interactions (Avoid): - Valproic acid: Increases lamotrigine plasma levels markedly; may cause toxicity. - Carbamazepine, phenytoin, phenobarbital: Induce metabolism, reducing lamotrigine concentrations and efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: Decrease lamotrigine levels; may need dose increase. - Serotonergic agents (e.g., SSRIs, SNRIs): Potential for increased risk of serotonin syndrome. - Rifampin: Enhances clearance, possibly lowering therapeutic effect. - Other enzyme inducers (e.g., primidone): May lower lamotrigine exposure.